Drops petrosian n 1 (n 2 - n 7 variants) for treatment of allergic and diatopically diseases of the eyes and nose

 

(57) Abstract:

The invention relates to medicine, for treatment of allergic and diatopically diseases of the eyes and nose. Drops contain kromolin sodium or nedocromil sodium or cromoglicate acid, dexamethasone-21-phosphate sodium salt, sterile buffer solution and, if necessary, ephedrine hydrochloride. Another option proposed drops includes kromolin sodium or nedocromil sodium or cromoglicic acid, diphenhydramine, buffer solution and, if necessary, dexamethasone-21-phosphate sodium salt and ephedrine hydrochloride. Another option drops includes kromolin sodium or nedocromil sodium, or cromoglicate acid and ephedrine hydrochloride buffer solution. Advantages of the proposed compositions are higher efficiency, lower side effects. These drops apply 1-2 drops in both halves of the nose and/or in both eyes 4-5 times a day. 3 S. and 4 C.p. f-crystals.

The invention relates to medicine, in particular to the treatment of allergic and diatopically diseases of the eyes and nose.

Known traditional separate application of antihistamines, sympathomimetics, corticosteroids for the treatment of Allergy and drops. This eye drops "Octadecanethiol containing a dexamethasone-21-phosphate of 0.1% [2]. Also known composition drops "Deksona" for the eyes and Sofradex" for the eyes, nose and ears [3]. Successfully apply the nose drops, consisting of prednisolone 0,05, ephedrine hydrochloride 0,1, Dimedrol 0,05, novocaine solution of 0.5% - 10 ml [4]. The disadvantage of these drugs is the lack of profilaktirujut immunological mechanism of action, warning the emergence and development of allergic and diatopically diseases of the eyes and nose, low efficiency in the treatment of these diseases.

The most similar content offered drops are drops for the eyes and/or nose, containing any drug interoperably group of substances that differ from each other equivalent signs and have shared significant technical equivalent sign inflamatornog immunological mechanism of inhibition of degranulation mastocytes (fat cells) and the allocation of these inflammatory mediators. These include drops "Bromohexyl" containing cromoglicic acid 2% [5], spray internalnode application "Tiled" containing nedocromil sodium, eye drops and nose "Lamusa", sodergard can be selected for the prototype. As a prototype of the claimed invention are considered the most widely used in Russia drops for eyes and nose "Iteral", consisting of the following components, wt.%/volume:

Kromolin sodium - 2

The benzalkonium chloride (as preservative) - 0,01

Sterile buffer solution - as required [7].

The disadvantage of this drug is that it does not possess anti-allergic and anti-inflammatory action, not pain acute manifestations of allergic and diatopically diseases of the eyes and nose, but only to some extent warns them. The effect of the application drops "Iteral" minor develops slowly, reaching a maximum within 2-4 weeks of starting treatment, this increases the incidence of idiosyncrasy to the drug.

The aim of the present invention is to eliminate the above drawbacks and increase the efficiency of the drops in the treatment of allergic and diatopically diseases of the eyes and nose by adding drops of new properties, allowing multi-dimensional impact on the disease, arising from anti-allergic, anti-inflammatory, local anesthetic, desensitization, acudose the m mechanism for the prevention of disease, and increase effectiveness by obtaining direct synergistic and potentiating properties in the inventive compositions, a significant decrease in the number and severity and side effects, obtain new properties, allowing to arrest the acute manifestations of the disease.

These goals are achieved by the fact that the drops for the treatment of allergic and diatopically diseases of the eyes and nose, containing kromolin sodium, a drug that has the technical equivalent sign interoperably group of substances, namely, an immunological mechanism of inhibition of degranulation mastocytes and allocation of these mediators of inflammation, providing profilaktirujut impact on the disease, also include in various embodiments, the dexamethasone-21-phosphate sodium salt, has anti-inflammatory, desensitizing and anti-allergic effects, diphenhydramine (diphenhydramine hydrochloride), providing an antihistamine, a local anesthetic, anti-inflammatory and reduces capillary permeability effect, ephedrine hydrochloride, calling vasoconstrictor and decongestant effects. A consequence of direct synergies and vzaimootmenyaemogo influence of ingredients compositionist multifaceted impact on the disease. The use of these drugs in the inventive compositions drops gives a qualitatively new healing properties, helps to arrest the acute manifestations of the disease, reduces the swelling and inflammation of the mucous membranes, which dramatically reduces the amount of discharge from eyes and nose, make contact inflamatornog ingredient with mucous, which increases the efficiency of its action. In turn interoperable profilaktirujut effect on the mucous increases the efficiency of the accompanying ingredients. This interaction leads to a rapid regression of the disease, can significantly reduce, in comparison with traditionally used used dosages of the components of the compositions. The use of lower dosages of the drugs, while maintaining a more pronounced action drops, explains the significant reduction of toxic and side effects. The presence of some of the compositions Dimedrol and/or dexamethasone-21-phosphate can prevent the occurrence of idiosyncrasy to intopathname component compositions. This is accomplished in seven cases drops. In the proposed composition N 1 are the ingredients in the following ratio, wt.%/volume:

Kromolin H5-0,1

Sterile buffer solution - as required

the basis of action which lies interoperably immunological mechanism in combination with desensitizing, anti-inflammatory and anti-allergic action of dexamethasone-21-phosphate. Drops are more effective well-known medicinal properties, direct and synergistic vzaimorezerviruemym effects, lower toxic and side effects, the ability to arrest the acute manifestations of the disease, to reduce the swelling and inflammation of the mucous membranes, the amount of discharge from eyes and nose, to prevent the development of idiosyncrasy to kromolin sodium.

In the song drops of N 2 are the ingredients in the composition, wt.%/volume:

Kromolin sodium or nedocromil sodium, or cromoglicate acid - 0,5-4,0

Dexamethasone-21-phosphate sodium salt - 0,05-0,1

Ephedrine hydrochloride - 1-5

Sterile buffer solution - as required

the basis of action which lies interoperably immunological mechanism in combination with desensitizing, anti-inflammatory and anti-allergic action of dexamethasone-21-phosphate, as well as vasoconstrictor and anti-inflammatory effect of ephedrine hydrochloride. Drop region is them and the article concludes that the effects lower technical and side effects, the ability to arrest the acute manifestations of the disease, to reduce the swelling and inflammation of the mucous membranes, the amount of discharge from eyes and nose, to prevent the development of indiosyncracies and kromolin sodium.

In the song drops N 3 ingredients used in the composition, wt.%/volume:

Kromolin sodium or nedocromil sodium, or cromoglicate acid - 0,5-4,0

Diphenhydramine - 0,1-0,5

Sterile buffer solution - as required

the basis of action which lies interoperably immunological mechanism in combination with an antihistamine, a local anesthetic, anti-inflammatory and reduces the permeability of the capillary action of demerol. Drops are more effective new therapeutic properties, direct and synergistic article concludes that the effects of lower toxicity and side effects, the ability to arrest the acute manifestations of the disease, reduce swelling, inflammation, pain and sensitivity of the mucous membranes, the amount of discharge from eyes and nose, to prevent the development of idiosyncrasy to kromolin sodium.

In the song drops N 4 ingredients used in the composition, wt.%/volume:

Kromolin sodium, Il is the first Sol - 0,05-0,1

Sterile buffer solution - as required

the basis of action which lies interoperably immunological mechanism in combination with an antihistamine, a local anesthetic, anti-inflammatory and reduces capillary permeability effect Dimedrol, as well as desensitizing, anti-inflammatory and antiallergic action dexamethason-21-phosphate. Drops are more effective than the prototype and a drop of N 1 and N 3, new therapeutic properties, direct and synergistic article concludes that the effects of lower toxicity and side effects, the ability to arrest the acute manifestations of the disease, reduce swelling, inflammation, pain and sensitivity of the mucous membranes, the amount of discharge from eyes and nose, to prevent the development of indiosyncracies to kromolin sodium.

In the song drops N 5 ingredients used in the composition, wt.%/volume:

Kromolin sodium or nedocromil sodium, or cromoglicate acid - 0,5-4,0

Diphenhydramine - 0,1-0,5

Ephedrine hydrochloride - 1-5

Sterile buffer solution - as required

the basis of action which lies interoperably immunological mechanism in combination with antihistamines, mastaan the living and anti-edematous action of ephedrine hydrochloride. Drops are more effective than the prototype and drops N 3, new therapeutic properties, direct and synergistic article concludes that the effects of lower toxicity and side effects, the ability to arrest the acute manifestations of the disease, reduce swelling, inflammation, pain and sensitivity of the mucous membranes, the amount of discharge from the eyes, to prevent the development of idiosyncrasy to kromolin sodium.

In the song drops N 6 ingredients used in the composition, wt.%/volume:

Kromolin sodium or nedocromil sodium, or cromoglicate acid - 0,5-4,0

Diphenhydramine - 0,1-0,5

Dexamethasone-21-phosphate sodium salt - 0,05-0,1

Ephedrine hydrochloride - 1-5

Sterile buffer solution - as required

based interoperably immunological mechanism in combination with an antihistamine, a local anesthetic, anti-inflammatory and reduces capillary permeability effect Dimedrol, as well as desensitizing, anti-inflammatory and anti-allergic action of dexamethasone-21-phosphate, as well as with vasoconstrictor and anti-inflammatory effect of ephedrine hydrochloride. Drops are more effective than the prototype and drops N 1 - N 5 and N eskimi and side effects the ability to arrest the acute manifestations of the disease, reduce swelling, inflammation, pain and sensitivity of the mucous membranes, the amount of discharge from eyes and nose, to prevent the development of idiosyncrasy to kromolin sodium.

In the song drops N 7 ingredients used in the composition, wt.%/volume:

Kromolin sodium or nedocromil sodium, or cromoglicate acid - 0,5-4,0

Ephedrine hydrochloride - 1-5

Sterile buffer solution - as required

the basis of action which lies interoperably immunological mechanism in combination with vasoconstrictor and anti-inflammatory effect of ephedrine hydrochloride. Drops are more effective than the prototype, new therapeutic properties, direct and synergistic article concludes that the effects of lower toxicity and side effects, the ability to arrest the acute manifestations of the disease, reduce swelling, inflammation of the mucous membranes, the amount of discharge from eyes and nose.

The analysis claimed the compositions reveals that the author of the improved three similar: kromolin sodium, nedocromil sodium and cromoglicate acid, each of which can be the prototype.

Composition otlichit hydrochloride. Thus, the claimed invention meets the criterion of "Novelty".

Analysis of the known preparations and compositions of the drops used to treat allergic and diatopically diseases of the eyes and nose, showed that all entered in the claimed solution of the substance is known, however, their use real or well-known songs, makes no such properties that they exhibit in the present decision and the absence of any of them in essential features is not possible to obtain a positive effect. The inventive solution is characterized by a new set of essential features and meets the criterion of "Substantial differences".

Direct and synergistic article concludes effects when using lower than srednestatisticheskiy, dosages of ingredients, the higher the efficiency of the drops and the effectiveness of treatment, the reduction of toxic and side effects from the use of drops, improving contact kromolin sodium with mucous due to a sharp reduce swelling and inflammation of the mucous membranes, as well as reducing the number of discharge from eyes and nose, properties, allowing to arrest the acute manifestations of the disease, gives grounds to do is izlagaemykh compositions for the treatment of allergic and diatopically diseases of the eyes and nose in comparison with analogues are significantly more high effectiveness, marked reduction of toxic and side effects from the use of lower than average therapeutic dosages of ingredients, the possibility of prolonged their application. The variety of compositions allows the main requirement for the treatment of allergic and diatopically diseases of the eyes and nose, namely the alternation of species drops every 5-7 days because of the possible development of the idiosyncrasies of the individual ingredients, as well as to prevent the development of side effects, such as tahifilaksii phenomenon or reduce the vasoconstrictive effect of sympathomimetics on 5-7 day of their application, and also facilitates the choice of drops including contraindications. Drops are used for a new purpose not only as profilaktirujut funds, but also for relief of acute manifestations of the disease. The use of drops does not require prior use of other drugs that restore the patency of the nasal passages. The choice of quantitative and qualitative component ratio takes into account gender, age, presence of contraindications. As an example, are most often used by the author of the compounds in the following ratio of ingredients:

trieva Sol - 0,05

Sterile buffer solution, ml To 100.0

N 2

Kromolin sodium or nedocromil sodium, or cromoglicate acid - 1,0

Dexamethasone-21-phosphate sodium salt - 0,05

Ephedrine hydrochloride - 1,0

Sterile buffer solution, ml To 100.0

N 3

Kromolin sodium or nedocromil sodium, or compilea acid - 1,0

Diphenhydramine - 0,3

Sterile buffer solution, ml To 100.0

N 4

Kromolin sodium or nedocromil sodium, or compilea acid - 1,0

Diphenhydramine - 0,2

Dexamethasone-21-phosphate sodium salt - 0,05

Sterile buffer solution, ml To 100.0

N 5

Kromolin sodium, or nedocromil sodium, or compilea acid - 1,0

Diphenhydramine - 0,2

Ephedrine hydrochloride - 1,0

Sterile buffer solution, ml To 100.0

N 6

Kromolin sodium or nedocromil sodium, or compilea acid - 1,0

Diphenhydramine - 0,2

Dexamethasone-21-phosphate sodium salt - 0,05

Ephedrine hydrochloride - 1,0

Sterile buffer solution, ml To 100.0

N 7

Kromolin sodium or nedocromil sodium, or cromoglicate acid - 1,0

Ephedrine hydrochloride - 2,0

Sterile buffer solution, ml To 100.0

Proposed drops Ispolin diseases of the eyes and nose. The majority of patients noted improvement in health, 21% of patients in remission for up to 6 months. The use of drops showed high efficiency for urgent conditions in patients with allergic and autopicking diseases of the eyes and nose, allergic angioedema in the eyes and nose.

All of these songs drops apply 1-2 drops for digging into both halves of the nose and (or) in both eyes 4-5 times a day at equal intervals of time is 4-5 hours. It is recommended that the alternation of the form of droplets in 7-10 days.

The use of drops Petrosian N 1 contraindicated in viral and fungal diseases of the eye and nose, acute purulent infections of the eyes and nose (in the absence of anti-infective therapy), intolerance to any ingredient. With long-term use drops some patients may experience increased intraocular pressure. Caution should be exercised when prescribing for children up to 5 years and pregnant women.

The use of drops Petrosian N 3 not allowed in case of intolerance to any ingredient, requires caution in children under 5 years and pregnant women.

The use of drops Petrosian N 5 and N 7 relative to protivoparaz what is very useful in chronic diseases of the myocardium, ray and in the elderly. Caution should be exercised when prescribing for children up to 5 years and pregnant women.

The use of drops Petrosian N 2, N 4, N 6 is contraindicated in viral and fungal diseases of the eye and nose, acute purulent infections of the eyes and nose (in the absence of anti-infective therapy). With long-term use drops some patients may experience increased intraocular pressure. Contraindicated appointment with hypertension, atherosclerosis, intolerance to any ingredient. Used with caution in chronic diseases of the myocardium, hyperthyroidism, the elderly, children under 5 and pregnant.

Sources of information

1. Picky Century. And., Adrianova N. In., Artamonova A. C. Allergic diseases. - M.: Medicine, 1991, (S. 194 and 205).

2.Mashkovsky M. D. Medicines. - Vilnius, 1994.

3. Nikolaev N. B., Alperovitch B. R., Sazanov C. N., Shih E. C. Reference Vidal. Drugs of foreign firms in Russia. ): Astra Pharm Service, 1995.

4. Chekman I. S., gritsyuk A. I., Grishchenko Century. And. Prescription reference of the doctor. - Kiev, 1985.

5. Romanovsky, C. E. New medicines in pharmacies Ro the other Essential medicines. - M: Medical center under the government of the Russian Federation, 1994, S. 113.

7. Instruction on the use of eye drops "Iteral", 1994.

1. Drops for treatment of allergic and diatopically diseases of the eyes and nose containing sterile buffer solution, characterized in that they additionally contain kromolin sodium or nedocromil sodium, or cromoglicate acid, dexamethasone-21-phosphate sodium salt in the following ratio, wt.%/ volume:

Kromolin sodium or nedocromil sodium, or cromoglicate acid - 0,5 - 4,0

Dexamethasone-21-phosphate sodium salt - 0,05 - 0,01

Sterile buffer solution - as required

2. Drops under item 1, characterized in that it further contain ephedrine hydrochloride in the amount of 1 - 5 wt.%/ volume.

3. Drops for treatment of allergic and diatopically diseases of the eyes and nose containing sterile buffer solution, characterized in that they additionally contain kromolin sodium or nedocromil sodium, or cromoglicate acid and diphenhydramine in the following ratio, wt.%/ volume:

Kromolin sodium or nedocromil sodium, or cromoglicate acid - 0,5 - 4,0

additionally contain dexamethasone-21-phosphate sodium salt in an amount of 0.05 - 0.1 wt.%/ volume.

5. Drops on p. 3, characterized in that it further contain ephedrine hydrochloride in the amount of 1 - 5 wt.%/ volume.

6. Drops on p. 3, characterized in that it further contains dexamethasone-21-phosphate sodium salt in a quantity of 0.05 - 0.1 wt.%/volume and ephedrine hydrochloride in the amount of 1 - 5 wt.%/volume.

7. Drops for treatment of allergic and diatopically diseases of the eyes and nose containing sterile buffer solution, characterized in that they additionally contain kromolin sodium or nedocromil sodium, or cromoglicate acid and ephedrine hydrochloride in the following ratio, wt. %/volume:

Kromolin sodium or nedocromil sodium, or cromoglicate acid - 0,5 - 4,0

Ephedrine hydrochloride - 1 - 5

Sterile buffer solution - How many trebuetsya

 

Same patents:
The invention relates to medicine, in particular to the means, possessing tonic and tonic effect, and can be used for General strengthening of the body, as well as for treatment of the gastrointestinal tract, upper respiratory tract, strengthen the cardiovascular system

The invention relates to medicine and relates to a method of obtaining herbal substances with adaptogenic activity

The invention relates to pharmaceutical industry and relates to biologically active agents derived from plant materials

The invention relates to medicine and for the preparation for the local treatment of superficial changes on the skin and mucous membranes, as well as for the treatment of infections of the skin and mucous membranes on the basis of the reaction of interaction between the solution of 1 - 5.5 M nitric acid with 45 - 170 mmol of primary C1- C5-alkanol on 1 l of nitric acid, as well as the way to obtain the drug

The invention relates to pharmaceutical technology and relates to a new pharmaceutical composition with analgesic activity
The invention relates to pharmaceutical industry, and in particular to improving technologies for injection K(Na) salt of benzylpenicillin (BP), which is used in medicine to treat diseases caused by gram-positive organisms and gram-negative cocci, and for the manufacture of various dosage forms based on it, such as: benzylpenicillin procaine salt, economically-1, bicillin-1, bicillin-3, bicillin-5, spectrum of antimicrobial action of which is similar to the spectrum of benzylpenicillin

The invention relates to new peptides with organizaitnal activity with high biological activity of the same type as the natural compound HRV, but with a shorter amino acid chain
The invention relates to medicine, namely to ophthalmology, and can be used to replace the moisture of the anterior chamber, and washing the anterior chamber of the eye and other tissues of the eye during surgery

The invention relates to medicine, namely to surgical wipes, used in the treatment of wounds and burns in all phases of wound healing

The invention relates to tetraethylammonium compounds of the formula I

< / BR>
and their pharmaceutically acceptable salts,

where R1represents one or more substituents selected from H, halogen, hydroxy, alkyl with 1 to 3 carbon atoms (optionally substituted by hydroxyl), alkoxyl with 1 to 3 carbon atoms, alkylthio with 1 to 3 carbon atoms, alkylsulfonyl with 1 to 3 carbon atoms, alkylsulfonyl with 1 to 3 carbon atoms, nitro, cyano, Polygalaceae with 1 to 3 carbon atoms, polyalkyloxy with 1 to 3 carbon atoms, phenyl (optionally substituted by one or more substituents selected from halogen, alkyl with 1 to 3 carbon atoms, alkoxy with 1 to 3 carbon atoms), or R1is carbamoyl, optional alkilirovanny one or two alkyl groups, each independently from 1 to 3 carbon atoms;

R2represents an aliphatic group containing 1 to 3 carbon atoms, optionally substituted by hydroxy or alkoxy containing 1 to 3 carbon atoms;

E represents alkylenes chain containing 2 to 5 carbon atoms, optionally substituted by one or more alkyl groups containing 1 to 3 atom is dinasovymi or different and are independently an alkyl of 1 3 carbon atoms, alkoxy with 1 to 3 carbon atoms, halogen, hydroxy, polyaluminum with 1 to 3 carbon atoms, polyalkyloxy with 1 to 3 carbon atoms, cyano, alkylthio with 1 to 3 carbon atoms, alkylsulfonyl with 1 to 3 carbon atoms, alkylsulfonyl with 1 to 3 carbon atoms, phenyl (optionally substituted by one or more substituents selected from halogen, alkyl with 1 to 3 carbon atoms or alkoxy with 1 to 3 carbon atoms), carbamoyl, optional alkilirovanny one or two alkyl groups, each of which is independently from 1 to 3 carbon atoms, or G represents a phenyl ring having condensed with him heterocyclic or aromatic carbocyclic ring,

and O-acylated derivatives
The invention relates to medicine, Nephrology

The invention relates to 6-[X-(2-hydroxyethyl)aminoalkyl]-5,11-dioxo-5,6,-dihydro-11H - indeno[1,2-C]isoquinolines of the General formula I

< / BR>
in which

X represents the number of carbon atoms equal to 0-5 in aminoalkyl group, located at the nitrogen atom in the 6 position of the canonical formulas indrosophila, to their salts with inorganic and organic acids and method of production thereof

The invention relates to water-soluble derivative of camptothecin described by formula (I)

< / BR>
where n = 1 or 2; 1) R1and R2taken separately, represent hydrogen, lower alkyl, (C3-7)cycloalkyl, (C3-7)cycloalkyl lower alkyl, lower alkenyl, hydroxy lower alkyl, lower alkoxy lower alkyl; 2) R1represents hydrogen, lower alkyl, (C3-7)cycloalkyl, (C3-7)cycloalkyl lower alkyl, lower alkenyl, hydroxy lower alkyl or lower alkoxy lower alkyl; R2is-COR3where R3represents hydrogen, lower alkyl, pergola-lower alkyl, (C3-7)cycloalkyl, (C3-7)cycloalkyl, lower alkyl, lower alkenyl, hydroxy lower alkyl, lower alkoxy, lower alkoxy lower alkyl; 3) R1and R2taken together with the connecting nitrogen atom form a saturated 3-7-atom heterocyclic group of formula 1A

< / BR>
where Y represents O, S, CH2, NR4where R4represents hydrogen, lower alkyl, pergola-lower alkyl, aryl, aryl substituted by one or more substituents selected from the group comprising lower alkyloxy lower alkyl, or COR5where R5represents hydrogen, lower alkyl, pergola-lower alkyl, lower alkoxy, aryl, aryl substituted by one or more substituents selected from the group comprising lower alkyl, pergola-lower alkyl, hydroxy lower alkyl, lower alkoxy lower alkyl; and their pharmaceutically acceptable salts, their use for the treatment of tumors and methods of preparation

The invention relates to new chemical substances possessing valuable properties, in particular derivatives pyridyl General formula (I)

< / BR>
where

n is the number 2, 3, 4 or 5,

A - uglerodsesola communication or unbranched Allenova group with 1 to 4 carbon atoms, unsubstituted or substituted by one or two alkyl groups,

X - nitromethylene group, cyanomethylene group, unsubstituted or substituted by a residue R6with the following for R4values except tetrazole, or a group of formula =N-R7where R7is cyano, alkanesulfonyl group, phenylsulfonyl group, phenylalkylamine group, aminosulfonyl group, alkylaminocarbonyl group, dialkylaminoalkyl group, phenylcarbonylamino group, aminocarbonyl group, alkylaminocarbonyl group or dialkylaminoalkyl group,

Y - alkoxygroup, fenoxaprop, allylthiourea, phenylthiourea or a group of the formula-R8NR9where R8means a hydrogen atom, an unbranched or branched alkyl group with 1 to 10 carbon atoms, which is in the 2nd, 3rd or 4th position can be C is POI or peredelnoj group, alkyl group with 1 to 4 carbon atoms, which may optionally be substituted with hydroxyl group in the 2 nd, 3rd or 4th position, cycloalkyl group with 3 or 4 carbon atoms, cycloalkyl group with 5-8 carbon atoms, in which one ethylene bridge can be replaced on-phenylenebis group, bicycloalkyl group with 6 to 8 carbon atoms, unsubstituted or substituted 1, 2 or 3 alkyl groups, adamantly group, alkoxygroup or trimethylsilylethynyl group, and R9is a hydrogen atom or an unbranched alkyl group, or R8and R9together with in between the nitrogen atoms form an unsubstituted or substituted by one or two alkyl groups or phenyl group, cyclic alkalinising with 4 to 6 carbon atoms, in which one ethylene bridge in the provisions of 3.4 can be replaced on-phenylenebis group, morpholinopropan or piperazinone, unsubstituted or substituted in the 4-position of the alkyl group with 1 to 3 carbon atoms or phenyl group,

R1is a hydrogen atom or an alkyl group with 1 to 3 carbon atoms,

R2and R3is a hydrogen atom or together form a carbon-carbon bond,

Pyr - Peregrina group, unsubstituted or sameena the group, alkylaminocarbonyl group, dialkylaminoalkyl group, group, translated in vivo metabolic by carboxyl group or carboxyl group, if Y represents the group R8NR9where R8and R9have the above meaning,

R5is a hydrogen atom or the halogen, alkyl, alkoxy or trifluoromethyl,

all of the aforementioned alkyl and CNS remains, if nothing else is mentioned, have 1 to 3 carbon atoms, and, if nothing else is mentioned, all the above-mentioned phenyl nuclei may be mono - or tizamidine identical or different substituents from the group comprising an atom of fluorine, chlorine, or bromine, alkyl, hydroxyl, alkoxyl, carboxyl, phenyl, nitro-, amino-, alkylamino, dialkylamino, alkanolamine, cyano, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminoalkyl, trifluoromethyl, alkanoyl, aminosulfonyl, alkylaminocarbonyl and dialkylaminoalkyl,< / BR>
their enantiomers, CIS - or TRANS-isomers, if R2and R3together denote a carbon-carbon bond, and their salts

The invention relates to the derivatives of decahydroquinoline formula active receptor antagonist amino acid-mediated excitation, which can find application in medicine, and to pharmaceutical compositions based on them
Up!